WUXIF
Neutral signalScored 2026-10-18 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
WuXi AppTec Co., Ltd.
- Nom
- WuXi AppTec Co., Ltd.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- OTC
- Capitalisation
- $67.0B
- Employés
- 33,834
- PDG
- Ge Li
- Site web
- https://www.wuxiapptec.com
- Marché
- CRLIQVMEDP
WuXi AppTec Co., Ltd., an investment holding firm, specializes in providing a full spectrum of research, development, and manufacturing services. The company's expertise is leveraged globally to facilitate the discovery, advancement, and production of both small molecule pharmaceuticals and innovative cell and gene therapies. Its operational reach extends throughout the People's Republic of China, across the broader Asian continent, within the United States, and across Europe. The organization is structured into six distinct divisions: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and a collective "Others" segment. WuXi AppTec offers comprehensive contract research, development, and manufacturing (CRDMO) capabilities, supporting new drug candidates from their initial discovery phases all the way to commercial launch. This support covers a diverse array of synthetic molecular compounds, such as small molecules, oligonucleotides, peptides, and intricate conjugates. Additionally, the company delivers biology services and solutions that underpin standalone or integrated projects, ranging from target identification to candidate selection and subsequent clinical progression. The firm also provides streamlined testing services for drugs and medical devices, spanning from preclinical evaluation to full-scale clinical trials. It further distinguishes itself by offering an integrated, end-to-end solution specifically designed to expedite the market entry of cell and gene therapies. Complementary services include drug discovery assistance for pharmaceutical and biotechnology clients, as well as comprehensive clinical research services. Founded in the year 2000, WuXi AppTec Co., Ltd. maintains its headquarters in Shanghai, People's Republic of China.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-18 17:07:39
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-18 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-18 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
WUXIF exhibits exceptional financial health (liquidity 90, fundamentals trend 85) with strong cash reserves, minimal debt, and robust profitability growth, providing a solid fundamental foundation.
The first sentence of the analysis written for WUXIF on 2026-10-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 3.21 · operating margin 37%
Recent news
- 2026-10-07 WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability SHANGHAI, Oct. 7, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for the third consecutive year, reflecting the Company''s consistent commitment to sustainability. EcoVadis is a leading sustainability rating agency for global supply chains.
- 2026-08-30 WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion SHANGHAI, Aug. 30, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend.
- 2026-08-21 Contrasting Sotera Health (NASDAQ:SHC) & WuXi AppTec (OTCMKTS:WUXIF) Sotera Health (NASDAQ: SHC - Get Free Report) and WuXi AppTec (OTCMKTS:WUXIF - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings. Insider and Institutional Ownership 91.0% of Sotera Health
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.6% | 41.5% | 41.1% | 37.3% | 36.3% | |
| Ebit Margin | 53.3% | 30.0% | 29.5% | 27.3% | 26.6% | |
| Ebitda Margin | 60.9% | 37.0% | 35.1% | 31.6% | 32.2% | |
| Operating Profit Margin | 37.4% | 29.5% | 29.4% | 27.1% | 26.4% | |
| Pretax Profit Margin | 52.6% | 29.4% | 29.3% | 27.0% | 26.3% | |
| Continuous Operations Profit Margin | 42.5% | 24.4% | 24.0% | 22.6% | 22.4% | |
| Net Profit Margin | 42.1% | 24.1% | 23.8% | 22.4% | 22.3% | |
| Bottom Line Profit Margin | 42.1% | 24.1% | 23.8% | 22.4% | 22.3% | |
| Current Ratio | 3.206 | 2.384 | 2.062 | 1.655 | 1.693 | |
| Quick Ratio | 2.739 | 2.052 | 1.741 | 1.264 | 1.238 | |
| Solvency Ratio | 0.989 | 0.576 | 0.655 | 0.591 | 0.390 | |
| Cash Ratio | 1.826 | 1.129 | 0.933 | 0.551 | 0.635 | |
| Price To Earnings Ratio | 14.194 | 15.154 | 21.752 | 24.541 | 61.706 | |
| Price To Earnings Growth Ratio | 0.136 | 12.275 | 2.847 | 0.341 | 0.948 | |
| Forward Price To Earnings Growth Ratio | 0.136 | 12.275 | 2.847 | 0.341 | 0.948 | |
| Price To Earnings Diluted Ratio | 14.387 | 15.247 | 21.752 | 26.195 | 62.419 | |
| Price To Earnings Diluted Growth Ratio | 0.140 | 24.700 | 1.460 | 0.416 | 0.964 | |
| Price To Book Ratio | 3.410 | 2.442 | 3.791 | 4.955 | 8.171 | |
| Price To Sales Ratio | 5.980 | 3.649 | 5.180 | 5.866 | 13.733 | |
| Price To Free Cash Flow Ratio | 23.302 | 17.043 | 26.551 | 355.002 | -134.023 | |
| Price To Operating Cash Flow Ratio | 15.801 | 11.543 | 15.610 | 21.748 | 68.535 | |
| Debt To Assets Ratio | 0.080 | 0.059 | 0.074 | 0.091 | 0.078 | |
| Debt To Equity Ratio | 0.104 | 0.081 | 0.099 | 0.126 | 0.111 | |
| Debt To Capital Ratio | 0.094 | 0.075 | 0.090 | 0.112 | 0.100 | |
| Long Term Debt To Capital Ratio | 0.022 | 0.048 | 0.012 | 0.016 | 0.016 | |
| Financial Leverage Ratio | 1.294 | 1.370 | 1.336 | 1.389 | 1.432 | |
| Working Capital Turnover Ratio | 1.401 | 2.058 | 3.206 | 4.255 | 1.897 | |
| Operating Cash Flow Ratio | 0.894 | 0.765 | 0.907 | 0.732 | 0.353 | |
| Operating Cash Flow Sales Ratio | 0.378 | 0.316 | 0.332 | 0.270 | 0.200 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.678 | 0.677 | 0.588 | 0.061 | -0.511 | |
| Debt Service Coverage Ratio | 3.673 | 8.614 | 3.217 | 2.653 | 2.716 | |
| Interest Coverage Ratio | 55.482 | 53.604 | 158.674 | 66.644 | 47.047 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.874 | 9.984 | 3.651 | 2.740 | 2.029 | |
| Operating Cash Flow Coverage Ratio | 2.083 | 2.613 | 2.455 | 1.810 | 1.071 | |
| Capital Expenditure Coverage Ratio | 3.106 | 3.099 | 2.427 | 1.065 | 0.662 | |
| Dividend Paid And Capex Coverage Ratio | 1.637 | 1.750 | 1.618 | 0.918 | 0.585 | |
| Dividend Payout Ratio | 0.259 | 0.326 | 0.287 | 0.181 | 0.179 | |
| Enterprise Value Multiple | 8.847 | 8.917 | 14.161 | 18.419 | 42.143 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.6% | ▲6.2% | ▲6.9% |
| Ebit Margin | 53.3% | ▲23.3% | ▲20.0% |
| Ebitda Margin | 60.9% | ▲23.9% | ▲21.6% |
| Operating Profit Margin | 37.4% | ▲7.9% | ▲7.4% |
| Pretax Profit Margin | 52.6% | ▲23.2% | ▲19.7% |
| Continuous Operations Profit Margin | 42.5% | ▲18.1% | ▲15.3% |
| Net Profit Margin | 42.1% | ▲18.1% | ▲15.2% |
| Bottom Line Profit Margin | 42.1% | ▲18.1% | ▲15.2% |
| Current Ratio | 3.207 | ▲0.822 | ▲1.006 |
| Quick Ratio | 2.739 | ▲0.687 | ▲0.932 |
| Solvency Ratio | 0.989 | ▲0.413 | ▲0.349 |
| Cash Ratio | 1.826 | ▲0.697 | ▲0.812 |
| Price To Earnings Ratio | 14.194 | ▼-0.960 | ▼-13.275 |
| Price To Earnings Growth Ratio | 0.136 | ▼-12.139 | ▼-3.173 |
| Forward Price To Earnings Growth Ratio | 0.136 | ▼-12.139 | ▼-3.173 |
| Price To Earnings Diluted Ratio | 14.387 | ▼-0.860 | ▼-13.613 |
| Price To Earnings Diluted Growth Ratio | 0.140 | ▼-24.560 | ▼-5.396 |
| Price To Book Ratio | 3.410 | ▲0.968 | ▼-1.144 |
| Price To Sales Ratio | 5.980 | ▲2.330 | ▼-0.902 |
| Price To Free Cash Flow Ratio | 23.302 | ▲6.260 | ▼-34.273 |
| Price To Operating Cash Flow Ratio | 15.801 | ▲4.258 | ▼-10.846 |
| Debt To Assets Ratio | 0.080 | ▲0.021 | ▲0.004 |
| Debt To Equity Ratio | 0.104 | ▲0.023 | ▼-0.001 |
| Debt To Capital Ratio | 0.094 | ▲0.019 | ▼-0.000 |
| Long Term Debt To Capital Ratio | 0.022 | ▼-0.026 | ▼-0.001 |
| Financial Leverage Ratio | 1.294 | ▼-0.076 | ▼-0.070 |
| Working Capital Turnover Ratio | 1.401 | ▼-0.658 | ▼-1.163 |
| Operating Cash Flow Ratio | 0.894 | ▲0.130 | ▲0.164 |
| Operating Cash Flow Sales Ratio | 0.379 | ▲0.062 | ▲0.079 |
| Free Cash Flow Operating Cash Flow Ratio | 0.678 | ▲0.001 | ▲0.379 |
| Debt Service Coverage Ratio | 3.673 | ▼-4.941 | ▼-0.502 |
| Interest Coverage Ratio | 55.483 | ▲1.879 | ▼-20.808 |
| Short Term Operating Cash Flow Coverage Ratio | 2.874 | ▼-7.110 | ▼-1.382 |
| Operating Cash Flow Coverage Ratio | 2.083 | ▼-0.530 | ▲0.076 |
| Capital Expenditure Coverage Ratio | 3.106 | ▲0.007 | ▲1.034 |
| Dividend Paid And Capex Coverage Ratio | 1.637 | ▼-0.113 | ▲0.336 |
| Dividend Payout Ratio | 0.259 | ▼-0.067 | ▲0.013 |
| Enterprise Value Multiple | 8.847 | ▼-0.070 | ▼-9.650 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $271.82B | $143.21B | $208.97B | $230.87B | $314.53B | |
| Enterprise value | $244.95B | $129.64B | $200.65B | $228.75B | $310.57B | |
| EV / Sales | 5.39x | 3.30x | 4.97x | 5.81x | 13.56x | |
| EV / Op. cash flow | 14.24x | 10.45x | 14.99x | 21.55x | 67.67x | |
| EV / Free cash flow | 21.00x | 15.43x | 25.50x | 351.74x | -132.34x | |
| EV / EBITDA | 8.85x | 8.92x | 14.16x | 18.42x | 42.14x | |
| Net debt / EBITDA | -0.97x | -0.93x | -0.59x | -0.17x | -0.54x | |
| Current ratio | 3.21x | 2.38x | 2.06x | 1.66x | 1.69x | |
| Income quality | 0.89x | 1.30x | 1.38x | 1.19x | 0.89x | |
| Graham number | $65 | $39 | $37 | $31 | $23 | |
| Graham net-net | $10 | $3 | $2 | -$2 | -$2 | |
| Tax burden | 80.1% | 81.9% | 81.2% | 83.0% | 84.7% | |
| Interest burden | 98.7% | 98.2% | 99.5% | 99.0% | 98.9% | |
| Working capital | $42.44B | $22.46B | $15.67B | $9.50B | $9.00B | |
| Invested capital | $71.23B | $50.66B | $44.91B | $35.75B | $27.92B | |
| Return on assets | 18.6% | 11.8% | 13.0% | 13.6% | 9.2% | |
| Operating ROA | 18.5% | 15.0% | 17.2% | 17.8% | 11.9% | |
| Return on tangible assets | 19.0% | 12.2% | 13.7% | 14.4% | 9.9% | |
| Return on equity | 24.0% | 16.1% | 17.4% | 18.9% | 13.2% | |
| Return on invested capital | 15.3% | 14.7% | 15.6% | 16.5% | 11.6% | |
| Return on capital employed | 20.3% | 18.1% | 20.2% | 21.2% | 14.3% | |
| Earnings yield | 7.0% | 6.6% | 4.6% | 3.8% | 1.6% | |
| Free cash flow yield | 4.3% | 5.9% | 3.8% | 0.3% | -0.7% | |
| Capex / Op. cash flow | 32.2% | 32.3% | 41.2% | 93.9% | 151.1% | |
| Capex / Depreciation | 159.4% | 143.9% | 241.6% | 588.5% | 539.5% | |
| Capex / Sales | 12.2% | 10.2% | 13.7% | 25.3% | 30.3% | |
| SG&A / Sales | 2.0% | 2.5% | 2.7% | 4.2% | 6.4% | |
| R&D / Sales | 2.5% | 3.2% | 3.6% | 4.1% | 4.1% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 2.2% | 2.7% | |
| Intangibles / Total assets | 2.1% | 3.2% | 5.0% | 5.6% | 6.4% | |
| Days sales outstanding | 68d | 85d | 83d | 0d | 0d | |
| Days payables outstanding | 38d | 28d | 25d | 25d | 104d | |
| Operating cycle | 206d | 171d | 156d | 84d | 148d | |
| Cash conversion cycle | 168d | 143d | 130d | 59d | 44d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
No employee-count data synced.